Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/ICI-118,551> ?p ?o }
Showing triples 1 to 64 of
64
with 100 triples per page.
- ICI-118,551 abstract "ICI-118,551 is a selective beta-2 (β2) adrenergic receptor antagonist. ICI binds to the β2 subtype with at least 100 times greater affinity than β1 or β3, the two other known subtypes of the beta adrenoceptor. The compound was developed by Imperial Chemical Industries, which was acquired by AkzoNobel in 2008. ICI-118,551 has no known therapeutic use in humans although it has been used widely in research to understand the action of the β2 adrenergic receptor, as few other specific antagonists for this receptor are known. When dissolved in saline, the compound crosses the blood–brain barrier. Common systemic doses used in rodent research are .5 or 1 mg/kg although efficacy has been demonstrated at doses as low as .0001 mg/kg in rhesus monkeys. Doses up to 20 mg/kg have been used without toxicity. At room temperature in saline, the ICI 118,551 hydrochloride is soluble to at least 2.5 mg/mL.".
- ICI-118,551 iupacName "3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol".
- ICI-118,551 thumbnail ICI_118551.svg?width=300.
- ICI-118,551 wikiPageID "18850804".
- ICI-118,551 wikiPageLength "3997".
- ICI-118,551 wikiPageOutDegree "15".
- ICI-118,551 wikiPageRevisionID "678922925".
- ICI-118,551 wikiPageWikiLink Adrenergic_receptor.
- ICI-118,551 wikiPageWikiLink AkzoNobel.
- ICI-118,551 wikiPageWikiLink Beta-1_adrenergic_receptor.
- ICI-118,551 wikiPageWikiLink Beta-2_adrenergic_receptor.
- ICI-118,551 wikiPageWikiLink Beta-3_adrenergic_receptor.
- ICI-118,551 wikiPageWikiLink Blood–brain_barrier.
- ICI-118,551 wikiPageWikiLink Category:Alcohols.
- ICI-118,551 wikiPageWikiLink Category:Beta_blockers.
- ICI-118,551 wikiPageWikiLink Category:Indanes.
- ICI-118,551 wikiPageWikiLink Category:Phenol_ethers.
- ICI-118,551 wikiPageWikiLink Imperial_Chemical_Industries.
- ICI-118,551 wikiPageWikiLink Ligand_(biochemistry).
- ICI-118,551 wikiPageWikiLink Receptor_antagonist.
- ICI-118,551 wikiPageWikiLink Rhesus_macaque.
- ICI-118,551 wikiPageWikiLink Saline_(medicine).
- ICI-118,551 wikiPageWikiLinkText "ICI-118,551".
- ICI-118,551 imagefile "ICI 118551.svg".
- ICI-118,551 iupacname "3".
- ICI-118,551 verifiedfields "changed".
- ICI-118,551 verifiedrevid "424696718".
- ICI-118,551 wikiPageUsesTemplate Template:Adrenergics.
- ICI-118,551 wikiPageUsesTemplate Template:Cascite.
- ICI-118,551 wikiPageUsesTemplate Template:Chembox.
- ICI-118,551 wikiPageUsesTemplate Template:Chembox_Hazards.
- ICI-118,551 wikiPageUsesTemplate Template:Chembox_Identifiers.
- ICI-118,551 wikiPageUsesTemplate Template:Chembox_Properties.
- ICI-118,551 wikiPageUsesTemplate Template:Ebicite.
- ICI-118,551 wikiPageUsesTemplate Template:Reflist.
- ICI-118,551 subject Category:Alcohols.
- ICI-118,551 subject Category:Beta_blockers.
- ICI-118,551 subject Category:Indanes.
- ICI-118,551 subject Category:Phenol_ethers.
- ICI-118,551 type Agent.
- ICI-118,551 type ChemicalCompound.
- ICI-118,551 type ChemicalSubstance.
- ICI-118,551 type Agent.
- ICI-118,551 type Alcohol.
- ICI-118,551 type Antagonist.
- ICI-118,551 type Antianginal.
- ICI-118,551 type Chemical.
- ICI-118,551 type Ether.
- ICI-118,551 type Hydrocarbon.
- ICI-118,551 type ChemicalObject.
- ICI-118,551 type Thing.
- ICI-118,551 type Q11173.
- ICI-118,551 comment "ICI-118,551 is a selective beta-2 (β2) adrenergic receptor antagonist. ICI binds to the β2 subtype with at least 100 times greater affinity than β1 or β3, the two other known subtypes of the beta adrenoceptor. The compound was developed by Imperial Chemical Industries, which was acquired by AkzoNobel in 2008.".
- ICI-118,551 label "ICI-118,551".
- ICI-118,551 sameAs Q6571514.
- ICI-118,551 sameAs ICI_118551.
- ICI-118,551 sameAs آیسیآی۱۱۸و_۵۵۱.
- ICI-118,551 sameAs m.04gprjj.
- ICI-118,551 sameAs ICI-118,551.
- ICI-118,551 sameAs ICI-118,551.
- ICI-118,551 sameAs Q6571514.
- ICI-118,551 wasDerivedFrom ICI-118,551?oldid=678922925.
- ICI-118,551 depiction ICI_118551.svg.
- ICI-118,551 isPrimaryTopicOf ICI-118,551.